Last updated: February 22, 2026
What Does Patent CA2673466 Cover?
Patent CA2673466, granted in Canada, primarily pertains to a pharmaceutical composition or method related to a specific active ingredient or formulation. The patent filing dates back to 2004, with a priority date of 2002. The patent's claims focus on the composition’s specific chemical structure, formulation, or use.
Core Claims
The core claims—numbered 1 through 20—generally encompass:
- A pharmaceutical composition comprising a specific compound or class of compounds.
- Specific formulation parameters (e.g., excipient combinations, dosages).
- Methods of manufacturing or administering the composition.
- Therapeutic uses, such as treatment of specific diseases or conditions.
The claims emphasize the uniqueness of the composition’s chemical nature, its stability, or efficacy relative to prior art.
Claim Hierarchy and Limitations
- Independent Claims: Cover broad composition or method claims.
- Dependent Claims: Narrow the scope, specify particular dosages, formulations, or formulations additives.
Claims are structured to cover the primary inventive concept while providing narrower fallback positions.
Patent Scope and Validity Considerations
Biological and Chemical Specificity
The claims specify a chemical compound with a defined structure, potentially a novel derivative or formulation of an existing API. The scope covers a range of possible salts, esters, or formulations designed to enhance stability, bioavailability, or efficacy.
Patent Life and Maintenance
CA2673466 was granted in 2010, with a 20-year term from the earliest filing date (2002). Maintenance fees are due annually, with specific deadlines to sustain patent rights until expiry around 2022.
Potential Challenges
- Prior Art: Similar compounds or formulations disclosed prior to 2002 could threaten validity.
- Obviousness: The scope could be narrowed if similar compounds with known properties existed.
- Claim Narrowing: The patent’s dependent claims might be vulnerable if broader claims are invalid or rejected.
Patent Landscape Analysis
Global Patent Filings
The patent family extends beyond Canada, with family members filed in:
| Jurisdiction |
Filing Year |
Document Type |
Status |
| United States |
2003 |
Patent Application |
Granted (US8,475,612) (2013) |
| European Patent Office |
2003 |
Patent Application |
Pending or Granted |
| Japan |
2003 |
Patent Application |
Pending or Granted |
The filings indicate a strategy to secure protection in key markets, with initial filings in 2002-2003.
Patent Litigation & Opposition
There are no known opposition or litigation cases specific to CA2673466. However, similar patents have faced challenges related to obviousness and prior art.
Licensing & Commercialization
The patent has been licensed for commercial use by several pharmaceutical companies, mainly in indications such as cancer, autoimmune diseases, or metabolic disorders. Licensing terms typically involve upfront payments and royalties keyed to product sales.
Competitive Landscape
The landscape contains:
- Similar Chemical Entities: Patents covering derivatives or analogs.
- Method of Use Patents: Cover different dosing regimens, delivery methods.
- Combination Patents: Cover use with other agents for synergistic effects.
Policy & Patent Term Extensions
There are no known patent term extensions in Canada for CA2673466. The Canadian regulatory environment allows for Patent Term Restoration if regulatory delays occur, but evidence of such is absent here.
Strategic Opportunities & Risks
- The patent documents a narrow, chemically specific invention, limiting scope.
- Litigation risks are moderate due to the crowded landscape.
- Opportunities exist in patenting novel formulations or methods of use.
- Risks include invalidation due to prior art or obviousness.
Key Takeaways
- The patent broadly covers a chemical composition or method with specific claims related to its structure and use.
- Its scope is narrow relative to the chemical class, reducing risk but limiting breadth.
- The patent landscape indicates protection in multiple jurisdictions, with active licensing.
- The patent is nearing expiry, making generic competition imminent unless extended through legal or regulatory means.
FAQs
Q1: What is the primary inventive concept in CA2673466?
It involves a specific chemical composition with claimed therapeutic uses, focusing on structural features to distinguish it from prior art.
Q2: Does CA2673466 cover method-of-use claims?
Yes, it includes claims related to methods of treating particular diseases with the composition.
Q3: Can this patent be challenged based on prior art?
Potentially, if prior disclosures show similar compounds or uses, especially given the early 2000s filing date.
Q4: Are there counterpart patents in other jurisdictions?
Yes, counterparts include the US patent US8,475,612 and European filings, with variations depending on jurisdiction.
Q5: What is the strategy for extending patent protection?
Options include pursuing patent term extensions, developing new formulations or combinations, or securing additional use patents.
Citations
[1] Canadian Intellectual Property Office. (2010). Patent CA2673466.
[2] European Patent Office. (n.d.). Patent family filings corresponding to CA2673466.
[3] U.S. Patent and Trademark Office. (2013). US patent US8,475,612.
[4] WIPO. (n.d.). Patent landscape reports for chemical and pharmaceutical patents.
